April 6, 2018 / 11:47 AM / 5 months ago

Incyte's combo therapy for skin cancer fails in late-stage study

April 6 (Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug in combination with Merck & Co’s Keytruda for a type of skin cancer failed to meet the main goal in a late-stage study.

The study did not meet the primary goal of improving progression-free survival in the population compared to Keytruda monotherapy, the two companies said.

Reporting by Mrinalini Krothapalli; Editing by Arun Koyyur

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below